Cilostazol Against a Borderline Ejection Fraction She Didn't Know She Had
Cilostazol is a Class I recommendation for her claudication, and she doesn't have diagnosed heart failure. An incidental echo finding sits close enough to the drug's real contraindication that the guideline's confidence stops feeling sufficient on its own.
C.P., a 66-year-old woman, spent decades working as a seamstress in a garment factory before it closed, and still hems and alters clothes for neighbors from her sewing room as a small side income. She has known peripheral arterial disease with an ankle-brachial index of 0.68, and lifestyle-limiting calf claudication — pain reliably onset after about one block of walking, which has started interfering with the short trips to deliver finished work that she used to make on foot. She completed twelve weeks of supervised exercise therapy alongside a high-intensity statin, with only modest improvement in her walking distance, bringing her back to discuss further options.
An echocardiogram obtained three months ago for an unrelated reason — a murmur her PCP wanted characterized — showed an ejection fraction of 48%, mildly reduced, asymptomatic, with no formal heart failure diagnosis and no prior cardiac symptoms of any kind. Cilostazol carries a Class 1 recommendation in the 2024 ACC/AHA multisociety peripheral artery disease guideline for exactly her situation, lifestyle-limiting claudication after a failed exercise-alone trial, with documented 40–60% improvement in walking distance; it also carries an absolute contraindication in heart failure of any severity, based on a class-wide mortality signal seen with other phosphodiesterase-III inhibitors in more advanced heart failure populations. She does not meet that formal contraindication — she has no heart failure diagnosis at all — but an ejection fraction of 48%, found incidentally and never followed up, sits close enough to that boundary that treating the guideline's Class I recommendation as the whole answer stopped feeling right the moment her echo came up in the chart.
At the vascular medicine follow-up
She's exactly who cilostazol is meant for — failed a genuine supervised exercise trial, lifestyle-limiting symptoms, no diagnosed heart failure. The guideline recommendation is Class 1, Level A, with real evidence behind it — 40 to 60% improvement in walking distance in the trials that established it. I'd start 100 mg twice daily.
I want to flag the EF of 48% directly rather than let it pass as background. She doesn't meet the formal contraindication, but that finding was incidental, never followed up, and we don't actually know its trajectory. Cilostazol's contraindication exists because of a class-wide mortality signal in heart failure, and an unconfirmed, borderline-reduced EF is close enough to that boundary that I'd want to know more before starting a PDE-3 inhibitor.
That's a fair asymmetry — the downside of waiting a few weeks for a repeat echo is small, and the downside of starting a drug with a real mortality signal in a population she might be quietly drifting toward is not. I'd rather confirm the EF trend first than either dismiss the finding or abandon cilostazol outright, given her claudication remains genuinely lifestyle-limiting and exercise alone has plateaued.
Cilostazol deferred pending a repeat echocardiogram in 4 weeks to confirm the ejection fraction finding and its trajectory. Supervised exercise and statin therapy continue unchanged in the interim.
Not agreed, and explicitly left as the open question the repeat echo is meant to answer, not resolve by itself:
Cilostazol likely proceeds as originally proposed, with the vascular medicine physician's original reasoning intact.
Cilostazol is off the table regardless of her claudication severity, and the cardiologist's caution will have been the more important read.